Dementia Clinical Trial
— LETHEOfficial title:
Digitally Supported Lifestyle Programme to Promote Brain Health Among Older Adults - the LETHE Pilot Trial
Verified date | June 2023 |
Source | Finnish Institute for Health and Welfare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Previous research has shown that a healthy lifestyle, including a balanced diet, physical and social activity, and management of vascular risk factors can support both cardiovascular and brain health. In a landmark Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), a multimodal lifestyle programme had clear benefits on older adults' cognition, functioning, and quality of life. The LETHE study utilises novel technologies and digital tools to deliver an optimised and more personalised FINGER-type multimodal lifestyle intervention. A total of 160 digitally skilled older adults (age 60-77) with risk factors for dementia but without substantial cognitive impairment will be recruited in Austria, Finland, Italy, and Sweden. Participants will be randomly assigned in a 1:1 ratio to the structured ICT-assisted multimodal lifestyle program (intervention group) or a self-guided lifestyle program (control group). Duration of the study and the intervention is 24 months. The multimodal lifestyle program covers the following domains: physical activity, nutrition, cognitive activity, vascular risk management, social interaction, sleep, and relaxation. The structured intervention program follows a hybrid model where regular in-person, individual and group-based intervention activities led by professionals are supported with activities in the LETHE mobile phone application. The self-guided (control) group receives relevant health advice and is recommended and encouraged to independently implement healthy lifestyle changes that are suitable and fit in with their daily routine. Control group will have access to a simplified version of the LETHE app without any structured, scheduled activities or personalized content. The primary objective of the LETHE trial is to test the feasibility of a digitally supported multimodal lifestyle program (i.e., retention rate, adherence to intervention), and assess change in dementia risk based on validated risk scores (CAIDE, LIBRA). Other objectives include testing the intervention effects on lifestyle and risk factors, cognition, function, health-related quality of life, health literacy, physical functioning, and dementia-related biomarkers. To this aim, a range of personal, lifestyle, and health-related data will be collected both actively and passively with the help of digital devices. Attitudes towards digital tools and experiences of trial participation will also be explored.
Status | Active, not recruiting |
Enrollment | 156 |
Est. completion date | March 31, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 77 Years |
Eligibility | Inclusion Criteria: - Age 60-77 years - Cardiovascular Risk Factors, Aging and Incidence of Dementia (CAIDE) Risk Score = 6 points - Cognitive performance at the mean level or slightly lower than expected for age, assessed with Mini-Mental State Examination (MMSE) and the Consortium to Establish a registry for Alzheimer's Disease (CERAD) verbal learning test (word list learning/recall) - Proficiency in the local language (German, Italian, Finnish or Swedish) - Ability and willingness to use an Android smartphone, access to and ability to use the internet (digital readiness) - Existing compatible smartphone (Android) or willingness to use a new Android smartphone provided from the study Exclusion Criteria: - Dementia or substantial cognitive impairment (e.g., memory clinic referral needed as judged by the study physician) - Current or past use of medications for Alzheimer's disease or related diseases (e.g., cholinesterase inhibitors, memantine) - Diminished decision-making capacity, not capable of consenting or completing study assessments, based on clinical judgement - Other significant neurologic disease, including but not limited to Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent neurologic sequelae or known structural brain abnormalities - Any condition affecting safe engagement in the intervention, e.g., malignant disease, major depression, symptomatic cardiovascular disease, revascularisation within 1 year previously - Severe loss of vision, hearing, or communicative ability; conditions preventing cooperation as judged by the study physician - Concomitant participation in an interventional trial (unless this will not interfere with the LETHE trial based on study staff's judgement) |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna | Vienna | |
Finland | Finnish Institute for Health and Welfare | Helsinki | |
Italy | University of Perugia | Perugia | |
Sweden | Karolinska Institutet | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Finnish Institute for Health and Welfare | Alzheimer Europe, Combinostics Oy, Extra Red s.r.l., FH Joanneum Gesellschaft mbH, Foundation for Research and Technology - Hellas (FORTH), Infotrend Innovations Co Ltd, Innovation To Grow, Kaasa solution GmbH, Karolinska Institutet, Lisbon Council, Maastricht University, Medical University of Vienna, Stichting EGI, University Of Perugia |
Austria, Finland, Italy, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory: Change in physical activity - self-reported, unit on a scale | Self-reported physical exercise in the previous two weeks, using a modified version of the Minnesota Leisure Time Physical Activity Questionnaire, as number of sessions and average duration for each of the activities listed in the questionnaire. Higher levels of physical activity indicate a better outcome.
Self-reported number of sessions of moderate-to-vigorous intensity exercise per week. A higher number of sessions indicates a better outcome. |
Baseline, 12 months, 24 months | |
Other | Exploratory: Change in physical activity - objective, based on Fitbit smartwatch | Objective measurement of physical activity levels, e.g., step count, using the Fitbit smartwatch which is worn continuously throughout the trial. Higher values indicate a better outcome. | Continuously for 24 months | |
Other | Exploratory: Change in dietary intake, unit on a scale | A brief food frequency questionnaire is used to calculate scores reflecting adherence to a healthy diet (MEDAS score reflecting adherence to Mediterranean-type diet; Healthy Diet Index score developed in Finland in the context of FINGER and type 2 diabetes prevention studies). Higher scores indicate a better outcome. | Baseline, 12 months, 24 months | |
Other | Exploratory: Change in individual cognitive domains, unit on a scale | Composite z-scores for the:
memory executive function processing speed domains that are included in the NTB used as a measure for the primary outcome. |
Baseline, 12 months, 24 months | |
Other | Exploratory: Change in cognition based on the digital assessment of cognitive performance (cCOG), unit on a scale | cCOG is a web-based self-administrable cognitive testing tool with three classical cognitive tasks: a modification of word list test, simple reaction task, and TMT. Higher scores and quicker performance indicate a better outcome. | 1 month, 13 months, 25 months (approx. 1 month after each main study visit and NTB assessment) | |
Other | Exploratory: Change in global cognition/function: Clinical Dementia Rating Sum of Boxes (CDR-SB), unit on a scale | CDR and CDR Sum of Boxes (CDR-SB) scores are used to assess the influence of cognitive impairment on the ability to conduct everyday activities in patients with Alzheimer's disease and give a global clinical impression of the patient. CDR-SB Score values range from 0-18, with lower scores indicating better outcome. | Baseline, 24 months | |
Other | Exploratory: Change in functioning level: Instrumental Activities of Daily Living (IADL), unit on a scale | Activity of Daily Living, Lawton-Brody Scale. Self-reported questionnaire assessing the level of functioning in eight daily activities necessary for living in the community. For each activity, the participant is rated either dependent (0 points) or independent (1 point). The score ranges 0-8, with a higher score indicating a better outcome. | Baseline, 12 months, 24 months | |
Other | Exploratory: Change in blood pressure, mmHg | Changes in systolic and diastolic blood pressure, lower measurements indicate better outcomes | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in Body Mass Index (BMI), kg/m² | Calculated using baseline height, with lower BMI value indicating better outcome | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in waist circumference, cm | Lower waist circumference value indicating a better outcome | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in concentration of blood lipids - total cholesterol, mmol/l | Measured from serum, a lower total cholesterol value indicates a better outcome. | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in concentration of blood lipids - HDL, mmol/l | Measured from serum, a higher HDL value indicates a better outcome. | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in concentration of blood lipids - LDL, mmol/l | Measured from serum, a lower LDL value indicates a better outcome. | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in concentration of blood triglycerides, mmol/l | Measured from serum with lower triglycerides value indicating a better outcome. | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in concentration of plasma glucose, mmol/l | Measured from fasting blood sample, with lower glucose value indicating a better outcome. | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in concentration of glycated haemoglobin (HbA1c), % | Measured from fasting blood sample, with lower HbA1c value indicating a better outcome. | Baseline, 6 months, 12 months, 24 months | |
Other | Exploratory: Change in heart rate, bpm | Heart rate measured with Fitbit smartwatch | Continuously for 24 months | |
Other | Exploratory: Change in amount of social interaction (based on the total count of nearby Bluetooth devices) | Data on the total count of nearby Bluetooth devices collected via passive mobile phone sensors. Higher values indicate better outcome. | Continuously for 24 months | |
Other | Exploratory: Change in physical functioning: timed 10-meter dual-task test, gait speed in m/s and gait cost | Timed 10-meter dual task test combines a physical task (walking 10m) with a cognitive task (e.g., naming letters of the alphabet). The result is the time in seconds needed to complete this activity; gait speed is calculated in m/s. Shorter time and higher gait speed indicates a better outcome. Gait cost identifies the percentage of speed that is lost by adding a task to the walking and it is calculated as: GC= [(single-task gait velocity - dual-task gait velocity) / single-task gait velocity] × 100. Lower percentage indicates a better outcome. | Baseline, 24 months | |
Other | Exploratory: Change in physical functioning: Short Physical Performance Battery (SPPB), unit on a scale | Short Physical Performance Battery (SPPB) is a group of measures that combines the results of gait speed (score range 0-4), chair stand test (score range 0-4), and balance test (score range 0-4). The total score (sum of three domains) ranges from 0 to 12 (higher scores indicating better performance). | Baseline, 24 months | |
Other | Exploratory: Change in physical functioning: hand grip strength, kg | Hand grip strength using a handgrip dynamometer. Higher measures indicate a better outcome. | Baseline, 24 months | |
Other | Exploratory: Change in depressive symptoms (Center for Epidemiologic Studies Depression Scale, CES-D), unit on a scale | The Center for Epidemiological Studies-Depression (CES-D) is a 20-item measure that asks how often over the past week symptoms associated with depression were experienced. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. | Baseline, 12 months, 24 months | |
Other | Exploratory: Change in sleep parameters based on Fitbit smartwatch data, unit on a scale | Changes in quantitative and qualitative parameters of sleep (sleep stages, duration, and fragmentation) measured by the Fitbit smartwatch | Continuously for 24 months | |
Other | Exploratory: Attitudes towards new technologies and novel digital solutions (System Usability Scale, SUS), unit on a scale | The SUS is a 10 item, widely used, psychometrically valid, and a simplified version is available for older adults with cognitive deficits. Scores are ranging 0-100 with higher scores indicating a better outcome. | 1 month, 6 months, 24 months | |
Other | Exploratory: Change in serum concentration of neurofilament light chain, NFL, pg/ml | Blood levels of neurofilament light chain protein range from a minimum of 0, with lower levels indicating a better outcome. | Baseline, 24 months | |
Other | Exploratory: Change in serum concentration of pTau-181, ng/uL | Blood levels of phosphorylated tau-181 range from a minimum of 0, with lower levels indicating a better outcome. | Baseline, 24 months | |
Other | Exploratory: Change in brain imaging markers: volumetry of brain segments based on magnetic resonance imaging, MRI | Volumes of specific brain regions are assessed computationally. | Baseline, 24 months | |
Other | Exploratory: Change in brain imaging markers: white matter lesions | White matter lesion load is assessed computationally. Lower values indicate a better outcome. | Baseline, 24 months | |
Other | Exploratory: Change in brain imaging markers: brain atrophy and vascular load, based on widely used rating scales, units on a scale | Medial temporal lobe atrophy (MTA), global cortical atrophy (GCA) and Fazekas are assessed computationally. Lower scores indicate better outcomes. | Baseline, 24 months | |
Other | Exploratory: Participant experiences of the trial and the usability, acceptability, and feasibility of the digital intervention tools | Qualitative data on the study experiences and opinions about the intervention and the LETHE App will be collected through interviews/focus groups with a subgroup of the intervention group participants. | 24 months | |
Primary | Feasibility: retention rate | Percentage of participants completing the 24-month trial period in each study arm. Higher percentage indicates a better outcome. | 24 months | |
Primary | Feasibility: adherence to the structured multimodal lifestyle intervention | Attendance at scheduled intervention sessions (percentage), usage of / engagement with the digital devices (LETHE App, Fitbit smartwatch). Possible values range from a minimum of 0, with higher values indicating better adherence and more active engagement. | Continuously measured during 24 months | |
Primary | Change in dementia risk scores (LIBRA and CAIDE), units on a scale | Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score and Change in the LIfestyle for BRAin health (LIBRA) score are validated tools to estimate late-life dementia risk based on a combination of non-modifiable and modifiable risk factors (CAIDE) or modifiable factors only (LIBRA). Total score ranges from 0 to 15 (CAIDE) and from -5.9 to +12.7 (LIBRA). Higher scores indicate higher risk. | Baseline, 12 months, 24 months | |
Secondary | Change in healthy lifestyle, unit on a scale | Change in Healthy Lifestyle Index (brief score developed in the FINGER trial), a composite score based on self-reported data on exercise, diet, vascular factors, and cognitive/social activity (range 0-24, with a higher score indicating a better outcome) | Baseline, 12 months, 24 months | |
Secondary | Change in cognition: composite z-score based on an extended Neuropsychological Test Battery (NTB), unit on a scale | The NTB used in this study is adapted from the FINGER trial and includes the following tests:
Wechsler Memory Scale Revised, WMS-III, WMS-R, logical memory, immediate WMS-R logical memory, delayed WMS-R visual paired associates, immediate WMS-R visual paired associates, delayed WMS-R Digit Span, total Rey Auditory Verbal Learning Test, RAVLT, learning (free recall) RAVLT, delayed recall CERAD category fluency Category fluency (fruits and vegetables) Trail Making Test (TMT) A Trail Making Test (TMT) B, shifting score B-A Stroop Test, shortened 40-stimulus version, condition 2 Stroop Test, condition 3, interference score 3 - 2 Wechsler Adult Intelligence Scale (WAIS) Digit Symbol Substitution Test (DSST) Higher z-score indicates better outcome (better cognitive performance). |
Baseline, 12 months, 24 months | |
Secondary | Change in stress-related symptoms (Perceived Stress Scale, PSS-14), unit on a scale | PSS is a 14-item self-report scale assessing stress-related symptoms. Values ranging 0-56, with lower scores indicating a better outcome. | Baseline, 12 months, 24 months | |
Secondary | Change in sleep problems (Insomnia Severity Index, ISI), unit on a scale | The Insomnia Severity Index (ISI) is a validated seven item assessment tool to assist in the clinical evaluation of insomnia complaints. Values ranging 0-28, with lower scores indicating a better outcome. | Baseline, 12 months, 24 months | |
Secondary | Change in health-related quality of life (RAND-36), unit on a scale | The RAND-36 is comprised of 36 items that assess eight health concepts. The scale values are ranging 0-100, with higher scores indicating a better outcome. | Baseline, 12 months, 24 months | |
Secondary | Change in health literacy (short version of the European Health Literacy Survey Questionnaire, HLS-EU-Q16), unit on a scale. | Health literacy will be assessed with the 16-item short version of the European Health Literacy Survey Questionnaire. Each item has four response categories (very difficult, fairly difficult, fairly easy and very easy), and higher scores indicate better health literacy. | Baseline, 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05686486 -
Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes
|
N/A | |
Terminated |
NCT05451693 -
Outreach-ER: A Dementia Care Intervention Program
|
||
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Enrolling by invitation |
NCT06040294 -
Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills
|
N/A | |
Completed |
NCT05114187 -
An Internet-Based Education Program for Care Partners of People Living With Dementia
|
N/A | |
Recruiting |
NCT06322121 -
Vascular Aspects in Dementia: Part 2
|
||
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT04426838 -
Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad
|
N/A | |
Recruiting |
NCT03462485 -
Pilot Study of the Effects of Playing Golf on People With Dementia
|
N/A | |
Active, not recruiting |
NCT03677284 -
Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia
|
N/A | |
Completed |
NCT03849937 -
Changing Talk Online (CHATO) Study
|
N/A | |
Recruiting |
NCT06284213 -
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
|
||
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Completed |
NCT04571697 -
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Recruiting |
NCT06033066 -
Financial Incentives and Recruitment to the APT Webstudy
|
N/A | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT05684783 -
Dementia Champions in Homecare
|
||
Completed |
NCT03147222 -
Function Focused Care: Fracture Care at Home
|
N/A |